Cabaletta Bio at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Cabaletta Bio brings 2 presentations to ESGCT 2026 in Hamburg. Its work covers CD19-directed CAR T cell therapy for autoimmune disease. One line reports early clinical and translational data in pemphigus vulgaris without lymphodepleting preconditioning, and another compares immune cell responses to CAR T cytokines across indications.
| Organization | ESGCT 2026 Attendance |
|---|---|
Cabaletta Bio Philadelphia, Pennsylvania | |
Develops CAR T cell therapies for autoimmune diseases, led by rese-cel, a CD19-directed CAR T. | Poster Wed Oct 28 1:30pm–3:30pm CD19-CAR T cell therapy without lymphodepletion preconditioning (PC-free) in pemphigus vulgaris: Early clinical and translational data with resecabtagene autoleucel, an autologous 4-1BB CD19-CAR T Poster Thu Oct 29 2:00pm–4:00pm Differential monocyte and macrophage responses to CAR T cell produced cytokines across Autoimmune Diseases may confer differential risk among indications |
Instantly find 20 buyers from Cabaletta Bio
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction